EP1230356A2 - Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes - Google Patents

Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes

Info

Publication number
EP1230356A2
EP1230356A2 EP00979564A EP00979564A EP1230356A2 EP 1230356 A2 EP1230356 A2 EP 1230356A2 EP 00979564 A EP00979564 A EP 00979564A EP 00979564 A EP00979564 A EP 00979564A EP 1230356 A2 EP1230356 A2 EP 1230356A2
Authority
EP
European Patent Office
Prior art keywords
pentraxin
nucleic acid
receptor
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979564A
Other languages
German (de)
English (en)
Inventor
Ramon Messeguer Peypoch
Elisabet Rosell Vives
Josep Ma Martinez Escola
Blanca Rodes Gubern
Jaume Adan Plana
Nuria Puig Calvo
Ana Carceller Rosa
Marc Masa Alvarez
Jaume Piulats Xanco
Izaak Den Daas
Ramon Trullas Oliva
Nuria De Gregorio-Rocasolano Barbany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to EP00979564A priority Critical patent/EP1230356A2/fr
Publication of EP1230356A2 publication Critical patent/EP1230356A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • Pentraxin I and Pentraxin receptor inhibitors of said proteins and pharmaceutical compositions containing said compounds
  • the present invention relates to nucleic acid sequences encoding the human Pentraxin receptor and related proteins as well as to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of (a) Pentraxin I or the human Pentraxin receptor, (b) a nonfunctional variant of the protein of (a) , (c) an antibody to the protein of (a) or (b) , (d) a nucleic acid sequence encoding the protein of (a) or (b) , (e) an antisense RNA sequence characterized in that it is complementary to a Pentraxin I or human Pentraxin receptor mRNA and can selectively bind to said mRNA, said sequence being capable of inhibiting the synthesis of Pentraxin I or the human Pentraxin receptor, or (f) a ribozyme characterized in that it is complementary to a Pentraxin I or human Pentraxin receptor mRNA and can selectively bind to and cleave said mRNA, thus inhibiting the
  • the present invention relates to the use of the above compounds for treating neuronal disorders or providing a neuroprotective effect.
  • the above compounds are useful for detecting a disease associated with a neuronal disorder based on a deregulated expression of the above proteins or the presence of Pentraxin I/human Pentraxin receptor having no or at least reduced biological activity.
  • Pentraxins are a family of proteins that include neuronal Pentraxin I (Ptx I) , neuronal Pentraxin II (Ptx II) and neuronal Pentraxin Receptor (Ptx R) as well as other non- neuronal members such as serum amyloid P protein (SAP) , C- reactive protein (CRP) and Pentraxin III which are cytokine- inducible acute phase proteins implicated in the immune response whose concentrations in the blood increase after an infection or a trauma event.
  • the proteins of the pentraxin family are characterized by their ability to form pentameric complexes and have been proposed to mediate the uptake of bacteria, toxins and extracellular debris in a calcium- dependent manner.
  • Pentraxin I was identified as a binding protein for the snake venom toxin taipoxin. mRNA of rat and human Pentraxin I has a large size (5.07 kb) , is localised in the nervous system and contains a signal peptide for extracellular export. It was suggested that Pentraxin I plays a role in removing synaptic debris and in neuronal plasticity. Rat neuronal pentraxin receptor has been identified through its binding to the snake toxin taipoxin and to other neuronal pentraxins . Rat pentraxin receptor contains a putative N-terminal transmembrane domain, suggesting that it can act as a receptor for different members of this family.
  • Rat Pentraxin II also called NARP (neuronal activity-regulated pentraxin) was described as an immediate- early gene that is rapidly induced in neurons of the hippocampus and cortex after synaptic activity. Pentraxin II seems to play a role in the modification of cellular properties related to long-term neuroplas t ici ty . Unfortunately, the exact physiological role of the members of the pentraxin family is unknown at the moment. On the other hand, so far the knowledge of compounds useful for treating neuronal diseases such as a stroke, an acute head trauma, multiple sclerosis and a spinal cord injury, or for providing neuroprotective effects is rather limited.
  • the technical problem underlying the present invention is to provide means for treating diseases associated with a neuronal disorder or for providing a neuroprotective effect.
  • the present invention relates a nucleic acid sequence encoding the human Pentraxin receptor or a protein exhibiting biological properties of the human Pentraxin receptor and being selected from the group consisting of
  • nucleic acid sequence which represents a fragment, derivative or allelic variation of a nucleic acid sequence specified in (a) to (c) .
  • a protein exhibiting biological properties of the human Pentraxin receptor is understood to be a protein having at least one of the activities of the human Pentraxin receptor as illustrated in the Examples, below.
  • the invention provides a nucleic acid sequence encoding the human Pentraxin receptor comprising the coding region of the nucleotide sequence depicted in Figure 19.
  • the present invention provides not only the nucleic acid sequence identified in Figure 19, but also a sample of plasmid DNA containing a human Pentraxin receptor cDNA.
  • the nucleotide sequence of the deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits.
  • the amino acid sequence of the protein encoded by the deposited clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human Pentraxin receptor encoding cDNA, collecting the protein, and determining its sequence.
  • the nucleic acid sequences of the invention can be both DNA and RNA molecules. Suitable DNA molecules are, for example, genomic or cDNA molecules. It is understood that all nucleic acid molecules encoding all or a portion of human Pentraxin receptor are also included, as long as they encode a polypeptide with human Pentraxin receptor activity.
  • the nucleic acid sequences of the invention can be isolated from natural sources or can be synthesized according to known methods .
  • the present invention also provides nucleic acid sequences which hybridize to the above nucleic acid sequences.
  • hybridize has the meaning of hybridization under conventional hybridization conditions, preferably under stringent conditions as described, for example, in Sambrook et al . , Molecular Cloning, A Laboratory Manual, 2 nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  • nucleic acid sequences that hybridize to the human Pentraxin receptor nucleic acid sequences at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency) ; salt conditions, or temperature.
  • washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
  • Variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
  • Nucleic acid sequences that hybridize to the nucleic acid sequences of the invention can be isolated, e.g., from genomic or cDNA libraries that were produced from rat or human cell lines or tissues. In order to identify and isolate such nucleic acid molecules the molecules of the invention or parts of these molecules or the reverse complements of these molecules can be used, for example by means of hybridization according to conventional methods (see, e.g., Sambrook et al . , supra) . As a hybridization probe nucleic acid molecules can be used, for example, that have exactly or basically the nucleotide sequence depicted in Figure 19 or parts of these sequences. The fragments used as hybridization probe can be synthetic fragments that were produced by means of conventional synthesis methods and the sequence of which basically corresponds to the sequence of a nucleic acid molecule of the invention.
  • nucleic acid sequences of the present invention also include molecules with sequences that are degenerate as a result of the genetic code.
  • the present invention provides nucleic acid sequences which comprise fragments, derivatives and allelic variants of the nucleic acid sequences described above encoding a protein of the invention.
  • “Fragments” are understood to be parts of the nucleic acid sequences that are long enough to encode one of the described proteins.
  • the term “derivative” in this context means that the sequences of these molecules differ from the sequences of the nucleic acid sequences described above at one or several positions but have a high level of homology to these sequences.
  • Homology hereby means a sequence identity of at least 40 %, in particular an identity of at least 60 %, preferably of more than 80 % and particularly preferred of more than 90 %.
  • proteins encoded by the nucleic acid sequences have a sequence identity to the amino acid sequence encoded by the nucleic acid sequence depicted in Figure 19 of at least 80 %, preferably of 85 % and particularly preferred of more than 90 %, 95 %, 97 % and 99 %.
  • the deviations to the above-described nucleic acid sequences may have been produced by deletion, substitution, insertion or recombination.
  • nucleic acid sequences that are homologous to the above- described sequences and that represent derivatives of these sequences usually are variations of these sequences that represent modifications having the same biological function. They can be naturally occurring variations, for example sequences from other organisms, or mutations that can either occur naturally or that have been introduced by specific mutagenesis. Furthermore, the variations can be synthetically produced sequences.
  • allelic variants can be either naturally occurring variants or synthetically produced variants or variants produced by recombinant DNA processes .
  • muteins can be produced, for example, that possess a modified Revalue or that are no longer subject to the regulation mechanisms that normally exist in the cell, e.g. with regard to allosteric regulation or covalent modification. Such muteins might also be valuable as therapeutically useful antagonists of human Pentraxin receptor.
  • nucleic acid sequences of the invention or parts of these sequences can be introduced into plasmids allowing a mutagenesis or a modification of a sequence by recombination of DNA sequences.
  • bases can be exchanged and natural or synthetic sequences can be added.
  • adapters or linkers can be added to the fragments.
  • manipulations can be performed that provide suitable cleavage sites or that remove superfluous DNA or cleavage sites. If insertions, deletions or substitutions are possible, in vitro mutagenesis, primer repair, restriction or ligation can be performed.
  • analysis method usually sequence analysis, restriction analysis and other biochemical or molecular biological methods are used.
  • proteins encoded by the various variants of the nucleic acid sequences of the invention show certain common characteristics, such as enzyme activity, molecular weight, immunological reactivity or conformation or physical properties like the el ec t r ophor e t i cal mobility, chromatographic behavior, sedimentation coefficients, solubility, spectroscopic properties, stability; pH optimum, and temperature optimum.
  • the invention furthermore relates to vectors containing the nucleic acid sequences of the invention.
  • they are plasmids, cosmids, viruses, bacteriophages and other vectors usually used in the field of genetic engineering.
  • Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria, the pMSXND expression vector for expression in mammalian cells and baculovirus-derived vectors for expression in insect cells.
  • the nucleic acid sequence of the invention is operatively linked to the regulatory elements in the recombinant vector of the invention that guarantee the transcription and synthesis of an RNA in prokaryotic and/or eukaryotic cells that can be translated.
  • the nucleotide sequence to be transcribed can be operatively linked to a promoter like a T7, metallothionein I or polyhedrin promoter.
  • the present invention relates to recombinant host cells transiently or stably containing the nucleic acid sequences or vectors of the invention.
  • a host cell is understood to be an organism that is capable to take up in vi tro recombinant DNA and, if the case may be, to synthesize the proteins encoded by the nucleic acid molecules of the invention.
  • these cells are prokaryotic or eukaryotic cells, for example mammalian cells, bacterial cells, insect cells or yeast cells.
  • the host cells of the invention are preferably characterized by the fact that the introduced nucleic acid sequence of the invention either is heterologous with regard to the transformed cell, i.e. that it does not naturally occur in these cells, or is localized at a place in the genome different from that of the corresponding naturally occurring sequence.
  • a further embodiment of the invention relates to human Pentraxin receptor or proteins exhibiting biological properties of the human Pentraxin receptor and being encoded by the nucleic acid sequences of the invention, as well as to methods for their production, whereby, e.g, a host cell of the invention is cultivated under conditions allowing the synthesis of the protein and the protein is subsequently isolated from the cultivated cells and/or the culture medium. Isolation and purification of the recombinantly produced proteins may be carried out by conventional means including preparative chromatography and affinity and immunological separations involving affinity chromatography with monoclonal or polyclonal antibodies, e.g. with the antibody described in the Examples, below.
  • the proteins of the invention not only comprise recombinantly produced proteins but include isolated naturally occurring proteins, synthetically produced proteins, or proteins produced by a combination of these methods . Means for preparing such proteins are well understood in the art.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one of the following compounds:
  • Pentraxin I refers to a protein or polypeptide being encoded by the nucleotide sequence as described in Perin et al . , Genomics 36, 1996, 543-545, the sequence of the GeneBank database accession no. U61849 or the nucleotide sequence shown in Figure 17, including Pentraxin I variants containing mutations or deletions which do not substantially affect the activity thereof.
  • Such mutations include substitutions of one or more amino acids, particularly by homologues thereof, as well as additions of one or more amino acids, especially at the N or C termini. Deletions include deletions from the N or C termini . Substitutions by both naturally-occurring and synthetic amino acids are possible.
  • Pentraxin I variants modified by chemical modification or enzymatic modification.
  • fragments of Pentraxin I are included within the definition of the term "Pentraxin I" .
  • a nonfunctional variant of the protein of (a) refers to a Pentraxin I variant or a human Pentraxin receptor variant which exhibits a substantial loss of biological activity or a complete loss of biological activity.
  • Such a variant may contain the modifications as described above for the human Pentraxin receptor or with respect to the definition of the term “Pentraxin I”, except that these modifications result in the generation of a "nonfunctional" Pentraxin I and human Pentraxin receptor.
  • Such a variant might be useful as an antagonist of the native protein.
  • an antibody to the protein of (a) or (b) relates to polyclonal or monoclonal antibodies, preferably, relates to antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations.
  • Monoclonal antibodies are made from an antigen containing fragments of Pentraxin I, the human Pentraxin receptor or the variants described above by methods well known to those skilled in the art (see, e.g., K ⁇ hler and Milstein, Nature 2556, 1975, 495-497) .
  • antibody As used herein, the term "antibody” (Ab) or “monoclonal antibody” (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. Thus, these fragments are preferred, as well as the products of a Fab or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.
  • nucleic acid sequence encoding the protein of (a) or (b) refers to the nucleotide sequence described by Perin et al . , supra, the GenBank sequence with the accession no. U61849 or the nucleotide sequence depicted in Figure 20 as regards Pentraxin I and to the nucleic acid sequences of the invention described above as regards the human Pentraxin receptor, e.g. the nucleic acid sequence shown in Figure 19.
  • These nucleic acid sequences can be both DNA and RNA molecules. Suitable DNA molecules are, for example, genomic or cDNA molecules.
  • nucleic acid sequences encoding all or a portion of Pentraxin I additionally comprise sequences as defined for the human Pentraxin receptor coding nucleic acid sequences, e.g. hybridizing sequences, fragments, derivatives, allelic variations etc..
  • the above definition also includes nucleic acid sequence encoding a nonfunctional Pentraxin I variant or nonfunctional human Pentraxin receptor variant which is, e.g., useful for "knocking out" the gene encoding the biologically active natural protein.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising (a) an antisense RNA sequence characterized in that it is complementary to an mRNA transcribed from a gene encoding Pentraxin I or the nucleic acid sequences of the invention encoding the human Pentraxin receptor or a protein exhibiting the biological activity of the human Pentraxin receptor or a part thereof and can selectively bind to said mRNA or part thereof, said sequence being capable of inhibiting the synthesis of Pentraxin I or the human Pentraxin receptor or a protein having the biological properties of the human Pentraxin receptor, or (b) a ribozyme characterized in that it is complementary to an mRNA transcribed from a gene encoding Pentraxin I or the nucleic acid sequences of the invention encoding the human Pentraxin receptor or a protein exhibiting the biological properties of the human Pentraxin receptor or a part thereof and can selectively bind to and cleave said mRNA or part thereof
  • Ribozymes which are composed of a single RNA chain are RNA enzymes, i.e. catalytic RNAs, which can intermolecularly cleave a target RNA, for example the mRNA transcribed from the Pentraxin I gene. It is now possible to construct ribozymes which are able to cleave the target RNA at a specific site by following the strategies described in the literature, (see, e.g., Tanner et al . , Antisense Research and Applications, CRC Press Inc. 1993, 415-426).
  • ribozymes are the catalytic domain and regions which are complementary to the target RNA and which allow them to bind to its substrate, which is a prerequisite for cleavage.
  • Said complementary sequences i.e., the antisense RNA or ribozyme, are useful for repression of Pentraxin I expression, e.g. for providing a neuroprotective effect.
  • the antisense RNAs and ribozymes of the invention are complementary to the coding region of the Pentraxin I/human Pentraxin receptor mRNA, e.g. to the 5' part of the coding region.
  • the person skilled in the art provided with the Pentraxin I/human Pentraxin receptor encoding nucleic acid sequences will be in a position to produce and utilize the above described antisense RNAs or ribozymes.
  • the region of the antisense RNA and ribozyme, respectively, which shows complementarity to the Pentraxin I/human Pentraxin receptor mRNA preferably has a length of at least 15, in particular of at least 25 nucleotides and particularly preferred is a length of at least 50 nucleotides.
  • the present invention relates to inhibitors which fulfill a similar purpose as the antisense RNAs or ribozymes mentioned above, i.e. reduction or elimination of biologically active Pentraxin I molecules or human Pentraxin receptor molecules.
  • Such inhibitors can be, for instance, structural analogues of the natural protein that act as antagonists.
  • such inhibitors comprise molecules identified by the use of the recombinantly produced Pentraxin I or human Pentraxin receptor, e.g. the recombinantly produced protein can be used to screen for and identify inhibitors, for example, by exploiting the capability of potential inhibitors to bind to the protein under appropriate conditions.
  • the inhibitors can, for example, be identified by preparing a test mixture wherein the inhibitor candidate is incubated with Pentraxin I or the human Pentraxin receptor under appropriate conditions that allow Pentraxin I or the human Pentraxin receptor to be in a native conformation.
  • Such an in vitro test system can be established according to methods well known in the art.
  • Inhibitors can be identified, for example, by first screening for either synthetic or naturally occuring molecules that bind to the recombinantly produced protein and then, in a second step, by testing those selected molecules in cellular assays for inhibition of Pentraxin I or the human Pentraxin receptor, as reflected by inhibition of at least one of the biological activities of said proteins as described in the Examples, below.
  • Such screening for molecules that bind Pentraxin I or the human Pentraxin receptor could easily performed on a large scale, e.g. by screening candidate molecules from libraries of synthetic and/or natural molecules.
  • an inhibitor is, e.g. a synthetic organic chemical, a natural fermentation product, a substance extracted from a microorganism, plant or animal, or a peptide.
  • the present invention relates to the use of one of the above disclosed compounds for the preparation of a pharmaceutical composition for preventing, treating or ameliorating a disease associated with a neuronal disorder or for providing a neuroprotective effect.
  • a disease examples include a stroke (brain ischemia) , an acute head trauma, multiple sclerosis, a spinal cord injury and Alzheimer disease.
  • the above compounds can be used as pro- apoptotic proteins. Particularly by overpression or upregulation of Pentraxin I, brain tumors can be treated.
  • suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.. Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose.
  • Administration of the suitable compositions may be effected by different ways, e.g. by intravenous, intraperetoneal , subcutaneous, intramuscular, topical or intradermal administration.
  • the route of administration depends on the nature of the disease and the kind of compound contained in the pharmaceutical composition.
  • the dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical arts, dosages for any one patient depends on many factors, including the patient's size, body surface area, age, sex, the particular compound to be administered, time and route of administration, general health and other drugs being administered concurrently.
  • nucleic acid sequences i.e. antisense RNAs or ribozymes
  • delivery of these nucleic acids can be achieved by direct application or, preferably, by using a recombinant expression vector such as a chimeric virus containing these compounds or a colloidal dispersion system.
  • desired target e.g., the intracellular expression of Pentraxin I and, thus, the level of Pentraxin I can be decreased resulting in the inhibition of the negative effects of Pentraxin I discussed above.
  • the above nucleic acids can be administered directly to the target site, e.g., by ballistic delivery, as a colloidal dispersion system or by catheter to a site in artery.
  • the colloidal dispersion systems which can be used for delivery of the above nucleic acids include macromolecule complexes, nanocapsules , microspheres, beads and lipid-based systems including oil-in-water emulsions, (mixed) micelles, liposomes and lipocomplexes .
  • the preferred colloidal system is a liposome.
  • the composition of the liposome is usually a combination of phospholipids and steroids, especially cholesterol.
  • the skilled person is in a position to select such liposomes which are suitable for the delivery of the desired nucleic acid molecule.
  • Organ-specific or cell-specific liposomes can be used in order to achieve delivery only to the desired site.
  • the targeting of liposomes can be carried out by the person skilled in the art by applying commonly known methods. This targeting includes passive targeting or active targeting (for example by coupling the liposome to a specific ligand, e.g., an antibody, a receptor, sugar, glycolipid, protein etc., by well known methods
  • Preferred recombinant vectors useful for gene therapy are viral vectors, e.g. adenovirus, adeno-associated virus (rAAV) , herpes virus such as herpes simplex virus type I (HSV I) , vaccinia, or, more preferably, an RNA virus such as a retrovirus .
  • the retroviral vector is a derivative of a murine or avian retrovirus.
  • retroviral vectors which can be used in the present invention are: Moloney murine leukemia virus (MoMuLV) , Harvey murine sarcoma virus (HaMuSV) , murine mammary tumor virus (MuMTV) and Rous sarcoma virus (RSV) .
  • a non-human primate retroviral vector is employed, such as the gibbon ape leukemia virus (GaLV) , providing a broader host range compared to murine vectors. Since recombinant retroviruses are defective, assistance is required in order to produce infectious particles.
  • GaLV gibbon ape leukemia virus
  • helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR.
  • Suitable helper cell lines are well known to those skilled in the art.
  • Said vectors can additionally contain a gene encoding a selectable marker so that the transduced cells can be identified.
  • the retroviral vectors can be modified in such a way that they become target specific. This can be achieved, e.g., by inserting a polynucleotid encoding a sugar, a glycolipid, or a protein, preferably an antibody.
  • Those skilled in the art know additional methods for generating target specific vectors. Further suitable vectors and methods for in vitro- or in vivo- gene therapy are described in the literature and are known to the persons skilled in the art; see, e.g., WO 94/29469 or WO 97/00957.
  • nucleic acid sequences encoding e.g. an antisense RNA or ribozyme can also be operatively linked to a tissue specific promoter and used for gene therapy.
  • tissue specific promoters such as myelin basic protein (MBP) promoter, neuron-specific enolase (NSE) promoter and glial fibrillary acidic protein (GFAP) promoter.
  • MBP myelin basic protein
  • NSE neuron-specific enolase
  • GFAP glial fibrillary acidic protein
  • Other tissue specific promoters are well known to those skilled in the art.
  • the above described compounds are particularly useful for preventing, treating or ameliorating a disease such as a stroke, an acute head trauma and brain tumors, e.g. a glioblastoma.
  • the present invention also relates to a method for detecting a disease associated with a neuronal disorder based on a deregulated expression of Pentraxin I or human Pentraxin receptor or the presence of Pentraxin I or human Pentraxin receptor having no or at least reduced biological activity comprising contacting a target sample suspected to contain Pentraxin I, human Pentraxin receptor or Pentraxin I or human Pentraxin receptor encoding nucleic acid sequences with a reagent which reacts with Pentraxin I or human Pentraxin receptor or the Pentraxin I or the human Pentraxin receptor encoding nucleic acid and detecting abnormal amounts or abnormal forms of Pentraxin I or the human Pentraxin receptor or Pentraxin I or human Pentraxin receptor encoding nucleic acid.
  • the reagent is typically a nucleic acid probe or a primer for PCR.
  • the person skilled in the art is in a position to design suitable nucleic acids probes based on the information as regards the nucleotide sequence of Pentraxin I and human Pentraxin receptor as depicted in Figures 20 and 19, respectively, or the literature disclosed above.
  • the reagent is typically an antibody probe (for the definition of the term "antibody probe” see the above definition of the term “antibody”) .
  • Detection methods include Northern blot analysis, RNase protection, in situ methods, PCR, LCR, immunoassays and other detection assays that are known to those skilled in the art.
  • the probes can be detectably labeled, for example, with a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, or an enzyme .
  • Pentraxin I or the human Pentraxin receptor in tissues can be studied with classical immunohistological methods.
  • Other antibody based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immun ' osorbent assay (ELISA) and the radioimmunoassay (RIA) .
  • ELISA enzyme linked immun ' osorbent assay
  • RIA radioimmunoassay
  • Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( 125 I, m I) , carbon ( 14 C) , sulfur ( 35 S) , tritium ( 3 H) , indium ( 112 In) , and technetium ( 99 mTc) , and fluorescent labels, such as fluorescein and rhodamine, and biotin.
  • enzyme labels such as, glucose oxidase, and radioisotopes, such as iodine ( 125 I, m I) , carbon ( 14 C) , sulfur ( 35 S) , tritium ( 3 H) , indium ( 112 In) , and technetium ( 99 mTc)
  • fluorescent labels such as fluorescein and rhodamine, and biotin.
  • Pentraxin I and the human Pentraxin receptor can also be detected in vivo by imaging.
  • suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject.
  • Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.
  • the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images.
  • the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99 mTc .
  • the labeled antibody will then preferentially accumulate at the location of cells which contain the specific protein.
  • the measured concentration is compared with the concentration in a normal tissue.
  • Further diagnostic methods include the determination of the size of the protein or the mRNA, the determination of the nucleotide sequence of • the Pentraxin I/human Pentraxin receptor gene by standard sequencing methods etc. and the comparison with the corresponding data obtained from a healthy individual.
  • kits are also provided by the present invention. Such kits are useful for the detection of a target cellular component, which is Pentraxin I and/or the human Pentraxin receptor or Pentraxin I and/or the human Pentraxin receptor encoding mRNA, wherein the presence of a decreased or increased concentration of the protein or mRNA or abnormal forms of the protein or corresponding nucleic acids (e.g.
  • said kit comprising (a) probe (s) which specifically bind(s) to Pentraxin I and/or the human Pentraxin receptor or Pentraxin I and/or the human Pentraxin receptor encoding nucleic acid sequences, e.g. mRNA.
  • the probe can be detectably labeled.
  • Such probe may be an antibody or oligonucleotide specific for the protein or the corresponding mRNA.
  • said kit contains an anti-Pentraxin I- antibody and/or an anti-human Pentraxin receptor-antibody and allows said diagnosis by ELISA and contains the antibody bound to a solid support, for example, a polystyrene microtiter dish or nitrocellulose paper, using techniques known in the art.
  • said kits are based on a RIA and contain said antibody marked with a radioactive isotope.
  • the antibody is labelled with enzymes, fluorescent compounds, luminescent compounds, ferromagnetic probes or radioactive compounds.
  • Table 1 Summary of the results of in situ hybridization of Pentraxin I. Expression of Pentraxin I mRNA at different times after the middle central artery occlusion (MCAO) in various brain regions: frontal cortex (left and right hemisphere) , piriform cortex (left and right hemisphere) and left hemisphere of hippocampus .
  • MCAO middle central artery occlusion
  • Table 2 Summary of the results of in situ hybridization of Pentraxin Receptor. Expression of Pentraxin Receptor mRNA at different times after the middle central artery occlusion (MCAO) in various brain regions: frontal cortex (left and right hemisphere), piriform cortex (left and right hemisphere) and hippocampus (left and right hemisphere) .
  • MCAO middle central artery occlusion
  • Figure 2 Gluta ate induced neurotoxicity in cerebellar granule cell cultures
  • Figure 5 Gene expression under permanent cerebral ischemia in rats
  • Figure 6 Northern analysis of rat Pentraxin I in cerebellar granule cells model after serum and potassium deprivation
  • Figure 7 Northern analysis of rat Pentraxin I (7/1) and Pentraxin receptor (7/II) in a stroke model
  • FIG. 8 mRNA levels of Pentraxin I and Pentraxin Receptor determined by a Real Time PCR (TaqMan) mRNA levels of Pentraxin I (panel A) and Pentraxin Receptor (panel B) were determined using the TaqMan technique. Samples used as a probes were derived from the left brain hemisphere (ischemic) of MCAO opperated rats, at different times. Material provided from sham animals or control animals (non opperated) was used as a control . The levels of Pentraxin I and Pentraxin Receptor, in reference of ⁇ -actin levels, showed a significative (*) increase.
  • TaqMan Real Time PCR
  • Figure 10 Detection by PCR of cDNA levels of Pentraxin I (10/1) and Pentraxin receptor (10/11) in several human cell lines
  • Figure 11 Detection by PCR of cDNA levels of Pentraxin I in several rat cell lines (11/1) and Pentraxin receptor in several rat cell lines (11/11) .
  • Figure 12 Pentraxin I (12/1) and Pentraxin receptor (12/11) expression by semiquantitative PCR at different culture conditions on the glutamate neurotoxicity model in rat cerebellar granule cells.
  • Figure 13 Effects of antisense and sense oligonucleotides on low potassium induced neuronal cell death in cerebellar granule cells (13/1) and in rat stroke model (13/11)
  • Figure 14 ELISA assay for detecting antibodies against rat Pentraxin I and Pentraxin receptor
  • the assay was done with peptide 1 (14/1; Pentraxin I) or respectively peptide 2 (14/11; Pentraxin receptor) conjugated with BSA using SMP or SPDP as a linker.
  • peptide 1 14/1; Pentraxin I
  • peptide 2 14/11; Pentraxin receptor
  • SMP or SPDP SMP or SPDP
  • FIG. 15 Western blot with cell lines using Pentraxin I
  • Figure 17 Western blott using a Pentraxin I monoclonal antibody on MCAO rat brain extracts.
  • Pentraxin I The protein levels of Pentraxin I were detected using a commercial monoclonal antibody (Transduction Laboratories, N35130) . After the MCAO stroke model, the rat brain was dissected in: right hemisphere, non-infarcted left hemisphere, infarcted left hemisphere and cerebellum. Samples were prepared as refered in further examples. The housekeeping gene tubuline was used as a control (ICN, 650952). Panel I shows the western blot using the control, tubulin, and the specific pentraxin I antibody.
  • Tubulin and pentraxin I were detected using the same antibodies referred in the figure 17.
  • the expression of pentraxin I was weekly detected in the control cells, whereas the expression in treated cells increased dramatically after the potassium depletion.
  • FIG. 19 Codifying region for human pentraxin receptor including the start codon (CTG) and the stop codon.
  • cytosine arabinoside (10 ⁇ M) 18 to 24h after plating.
  • the cultures were incubated at 37 S C in 5% C0 2 in air saturated with water vapor.
  • the cells were used for the experiments described above after 8 days in culture.
  • Neurotoxicity was induced in cells maintained in culture 8 days. Conditioned medium from native cultures was reserved for later use. Cultures were washed twice with modified Locke's buffer without magnesium and glucose (154 mM NaCl, 5.6 mM KC1, 2.3 mM CaCl 2 , 8.6 mM HEPES, 10 ⁇ M glycine, pH 7.4) . After 40 minutes preincubation, fresh Locke's buffer containing 10 ⁇ M glycine and 100 ⁇ M glutamate was added and cultures were incubated for 1 hour at 37 2 C. After then cultures were rinsed once, conditioned medium was reintroduced and cells were returned to the incubator (Figure 2) .
  • RNA extraction was processed for RNA extraction (see description for RNA isolation) , immediately (lh sample) or after 3 hours (4h sample) .
  • other culture conditions were assayed: a) glucose deprivation in Locke's buffer, without glutamate induction, b) glucose 5 mM Locke's buffer and glutamate induction. In both cases RNA extractions were done at lh and 4h. The 8 days culture was considered as a control.
  • PTX1AS GCGTGCGGCGCGGCCGGCCAG antisense PTX1S CTGGCCGGCCGCGCCGCACGC sense
  • a concentration of 10 ⁇ M ODN was found to be optimal for "antisense knockdown" .
  • Either sense or antisense ODN were added immediately after switching granule cell cultures from high to low potassium media.
  • Viable neurons were quantified by simultaneously staining with two fluorescent dyes, fluorescein diacetate (FD) and propidium iodide (PI) , 24 h after potassium deprivation. The stained cells were examined with a standard epi-illumination fluorescence microscope and pictures were taken.
  • Neuronal cell death was expressed as % cell death obtained as follows: PI positive cells X 100 / (PI positive + FD positive cells).
  • the focal permanent Stroke Model involves the occlusion of the left middle cerebral artery (MCA) in the rat following the subtemporal approach with diathermy occlusion described by Tamura et al . , (J. Cereb Blood Flow Metab, 1981, 53-60) and modified according to Bederson et al . , (Stroke 17, 1986, 472-478; Stroke 17, 1986, 1304-1307).
  • MCA left middle cerebral artery
  • Fischer-344 rats male, 230-260 gr .
  • Permanent left common carotid artery occlusion was carried out by double ligature with fine suture silk, for improving the reproducibility of infarction. Skin and temporal muscle were cut with scissors without damaging the facial nerve.
  • the skull was opened with a drill in continuous saline flow and distal left middle cerebral artery was exposed transcranially without damage of zygomatic bone.
  • the Dura Mater was disrupted with a 10/0 needle.
  • the MCA was lifted off distally and occluded using fine bipolar forceps
  • the brains were removed after 2h, 6h, 8h, 24h, 7d, 14d or
  • RNA for the assays reported in B, C and D
  • the left and right hemispheres were frozen separately in liquid nitrogen, and the same was done for the cerebellum.
  • the surgical process for sham rats was the same than the operated animals but the electrocoagulation of the MCA.
  • the brain was removed after 24 hours and is treated as usual.
  • the infarcted areas were quantified by image analysis.
  • RNA isolation from the stroke model left and right hemisphere and cerebellum from intact and ischaemic rats were frozen in liquid nitrogen. Three to five samples from each treatment were pooled and RNA was extracted, according to Chomczynsky et al . , Analytical Biochemistry 162, 1987, 156- 159) and purified in a CsCl gradient (Sambrook et al , supra) . mRNA was purified using an oligo-dT column. RNA from cell model was extracted as follows: at the indicated times the culture medium was removed from the flasks and the cells were washed twice with RNase free PBS buffer. Guanidinium isothiocyanate buffer was added directly into the flask.
  • RNA synthesis was carried out using the "You-prime first-Strand Beads" -kit from Amersham Pharmacia Biotech with 1 ⁇ g of mRNA and ImM of the appropriate oligonucleotides. All the steps involving RNA manipulation were done with DEPC treated material and solutions according to general protocols (Sambrook et al . , supra)
  • RNA from the stroke model (sham, 2 and 6 hours from left hemisphere) and the granule cells under serum and potassium deprivation (control, 2 and 4 hours) were used in the "Differential Display” (DD) -experiments .
  • the method used was the originally described (Liang and Pardee, Science 257, 1992, 967-971) .
  • the 12 oligonucleotides used for sscDNA synthesis were (dT) xl VN (downstream oligonucleotides) .
  • Amplification of the sscDNA was conducted with the same 3' oligonucleotide and a second decamer arbitrary 5' oligonucleotide (upstream oligonucleotide) .
  • PCR amplification products were analyzed on a denaturing 6% polyacrylamide gel (Genomyx) in a Genomyx LR apparatus. Gels were run at 800V for 16 h. DNA was visualized by silver staining, and dried ( Figure 3) . DNA bands corresponding to differentially regulated genes were cut out from the gel .
  • DNA was eluted from the gel by immersion in 10 ⁇ l of H 2 0 for 2 h at -20°C, and reamplified using the same pair of oligonucleotides and the same PCR conditions.
  • the resulting bands were directly cloned into the "pGem-T Easy" -vector (Promega) , and three positive clones sequenced (Silver sequence system from Promega) . In the case that the three clones had the same sequence, it was assumed that they correspond to the band selected from the gel and there was only one. Sequences were compared to genomic databases. Validation of the obtained bands was done initially by Reverse Northern. Positive ones were further analyzed by Northern and/or semi-quantitative and quantitative PCR.
  • Northern blots were performed with 5 ⁇ g of mRNA samples from the stroke model (left and right hemisphere and cerebellum from intact and sham, and 2 h, 6 h, 8 h, 24 h, 7d, 14 d and 21 d ischaemic rats) , the cell cultures under glutamate treatment or the cells deprivated of serum and potassium. Rat Pentraxin I and Pentraxin receptor, respectively, was radioactively labeled and used as a probe. mRNA amount per sample was checked using actin. Membranes from human tissues and dissected brains were purchased from Clontech. Hybridizations were done with actin and a subclone of human Pentraxin I.
  • Human Pentraxin I was cloned by PCR using a set of specific oligonucleotides corresponding to the coding region. The complete cDNA was previously published (mouse and human neuronal Pentraxin I (Perin et al, supra)) and the sequence can be found in the GenBank database (accession U61849) . This allowed to design the specific primers for PCR cloning. Human RNA samples from brain cortex, hippocampus and cerebellum as well as cDNA from total brain purchased from Clontech were used.
  • the primers were designed only for the coding region (bases 138 to 1431) .
  • Several cDNA clones were obtained. One of these clones includes a fragment from base 723 to 1328 ( Figure 20) .
  • the cDNA sequence for the human Pentraxin receptor was deduced from a genomic sequence found in the EMBL databank (accession number: HS327J16) using the sequence from the rat Pentraxin receptor previously published (Dodds et al . , J. Biol. Chem. 272, 1997, 21488-21494) (accession number: AF005099) .
  • a homology search was conducted in public data banks and fragments of one genomic sequence were found that showed homology to the coding region of the gene (accession AL008583). The fragments corresponding to putative exons have a 85% of similarity with the coding region of the rat sequence. This allowed to design specific primers for PCR cloning.
  • Human brain tissue and brain cDNA purchased from Clontech were used.
  • rat Pentraxin I forward 1390/1410: AGGCCAACGAGCTGGTCCTCA; reverse 1795/1777 TGGGATTCAGCCCAGGCGA
  • rat Pentraxin receptor forward 950/979: CCGGCAGAGGCAGGAAGTGGAAAAGGAGTT; reverse 1574/1549 GCCTCTACCAGCTTGTCTTCCCAGGG
  • actin forward CGATATCGCTGCGCTCGTCG ; and reverse: ATCTCCTTCTGCATCCTGTC
  • Forward primers were labelled with biotin-UTP. Samples were removed from each cycle from the 15th to the 30th in order to determine the exponential phase of the gene amplification.
  • the PCR product was electrophoresed and transferred to a nylon membrane. After quimioluminiscent detection, the films were scanned, and the intensity of the bands was measured. Ratios between actin and Pentraxin I or Pentraxin receptor were computed, and the values of the same cycle for different samples were compared.
  • rat Pentraxin I and Pentraxin Receptor were examined by the Real Time TaqMan PCR technique using a ABI PRISM® 7700 Sequence Detection System (Applied Biosystems) . With this technique, absolute concentrations of cDNA can be measured with high sensitivity. Special primers with a length of 25 and 29 bp and a 32-mer probe (reporter dye: FAM / quencher dye: TAMRA) were designed following the commercial indications .
  • Rats subjected to MCAO were sacrificed at 6 and 24 hours, and 7 days post occlusion and perfused with 0.1 M phosphate buffer followed by 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were dissected out, post-fixed in the same fixative for 8 hr at 4 a C and cryoprotected in 10% sucrose solution. 20 ⁇ m thick coronal sections were cut in a cryostat, mounted in sylane treated slides and stored at -40 2 C. Intact rats were used as control.
  • Plasmid DNA containing a rat Pentraxin I fragment or a rat Pentraxin receptor fragment was linearized with selected restriction enzymes, phenol/chloroform extracted and ethanol precipitated. The pellet was resuspended in 25 ⁇ l of H 2 0, and the concentration measured under UV. 1 ⁇ g of purified linearized plasmid was transcribed using either T7 , T3 or Sp6 RNA polymerases with the "Dig RNA labeling" -kit from Roche Diagnostics. The yield of labeled RNA was estimated using labeled control RNA from the same kit in a dot blot procedure. Riboprobes were used at 250 to 500 ng/ml .
  • sections were sequentially hydrated in PBS and incubated with 0.2% of Triton-XlOO in PBS. Sections were then treated with 0.2 N HCl (10 min) and acetylated in 0.1 M triethanolamine, 0.25% acetic anhydride (5 min). Then, sections were post-fixed in 4% paraformaldehyde (10 min) , washed in PBS, rinsed in 0.025 M glycine (5 min) and sequentially dehydrated in ethanol (50,70,90 and 100%).
  • Sections were prehybridized with hybridization buffer containing 50% formamide, 20% dextran sulfate, 5% Denhardt solution, 2% 0.5 M EDTA, 2% 1 M PIPES, 0.2% SDS, 5% 1 M DTT, 2.5% 10 mg/ml ssDNA, 2.5% 10 mg/ml yeast-tRNA and 10% 20xSSC (2hr at 60 2 C) and subsequently hybridized in the same buffer containing 400 ng/ml probe (overnight at 60 2 C) . After hybridization, sections were washed twice in 2xSSC and treated with 20 ⁇ g/ml RNase A in 0.01 M Tris-HCl pH 7.5 (1 hr, 37 S C) . After, sequential stringency washes were done with 2xSSC, lxSSC, 0.5xSSC (15 min each at room temperature) and O.lxSSC (30 min at 60 2 C) .
  • Sections were subsequently blocked with 1% BSA in Tris-buffer pH7.5 (2 h at room temperature) and incubated with sheep polyclonal anti-digoxigenin antiserum conjugated with alkaline phosphatase in Tris-buffer pH7.5 (overnight at 4 S C) . Then, sections were washed and color was developed incubating with BCIP/NBT for several hours.
  • a synthetic peptide was designed for the raising of specific antibodies based on the sequence of Rat Pentraxin I and the rat Pentraxin receptor, respectively. For the design two principal aspects were considered: the high homology between the members of the pentraxin family and the accessibility of the aminoacids residues.
  • Figure 4 shows the sequence of the peptides. For the prediction of protein structures conventional methods were used.
  • Synthetic peptides were linked to a carrier (BSA or KLH) using two commercial linkers: SMP (N-succinimidyl 3- maleimidopropionate ) and SPDP (N-succinimidyl 3- (2- pyridyldithio-propionate) both from Pierce following the manufacturer recommendations .
  • SMP N-succinimidyl 3- maleimidopropionate
  • SPDP N-succinimidyl 3- (2- pyridyldithio-propionate
  • Polyclonal antibodies against synthetic peptides were obtained after intraperitoneal (i.p.) administration of conjugated KLH peptides and Ribi as adjuvant in balb/c mouse. A second dose was administrated 21 days after the first one, and the serum was extracted at day 31. 50 ⁇ g of peptide was used per dose and 10 animals per peptide. The presence of specific antibodies in the serum was tested using a standard ELISA method. In order to avoid a cross-reaction the coating of ELISA plates was performed using SMS-BSA peptide and peptide-SPDP-BSA at 1 ⁇ g/ml.
  • B cells from the spleen of immunised mouse were fused with Friendly Myeloma-653 (Vertex) cells as a partner using PEG following the standard method (Kohler and Milstein, supra) .
  • SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • a concentration of 10 ⁇ M ODN was found to be optimal for "antisense knockdown" .
  • Either sense or antisense ODN were added immediately after switching granule cell cultures from high to low potassium media.
  • Viable neurons were quantified by simultaneously staining with two fluorescent dyes, fluorescein diacetate (FD) and propidium iodide (PI) , 24 h after potassium deprivation. The stained cells were examined with a standard epi-illumination fluorescence microscope and pictures were taken. Neuronal cell death was expressed as % cell death obtained as follows: PI positive cells X 100 / (PI positive + FD positive cells) . (M) Antisense assay on in vivo model.
  • phosphorothioate analogues of 21-mer antisense oligodeoxyribonucleotides to the rat Pentraxin I and rat Pentraxin receptor transcripts used were as follows: PTX I AS GCGTGCGGCGCGGCCGGCCAG rat pentraxin I antisense PTX R AS GATGACGGCACCGAGGAACGC rat pentraxin receptor antisense
  • Each antisense assay had two control groups: a group treated with the vehicle (saline solution) and another group treated with a control oligonucleotide.
  • phosphorothioate analogues of 21-mer control oligodeoxyribonucleotides to the rat Pentraxin I and rat Pentraxin receptor transcripts used were as follows: PTX I S CTGGCCGGCCGCGCCGCACGC rat pentraxin I sense PTX R MIS GATTACAGCACTGAGAAACGC rat pentraxin receptor mismatch
  • the treatments were applied by infusion into the left brain cortex of the rat, through a cannula guide implanted in the co-ordinates (AP -1.6, L +5.5, P -1.0) corresponding to the core of the infarcted area.
  • the oligonucleotides were administered at 10 ⁇ M, at 0.5 ⁇ L/minute for 2 minutes.
  • the final amount of oligonucleotide in each administration was lOnmols.
  • the animals in the control group received 1 ⁇ L of saline solution.
  • Each animal received four administrations as follows: the first administration was performed 48 hours before MCA occlusion (MCAO) , the second 24 hours before MCAO, third was done 5 minutes after MCAO and the last was done 24 hours after injury.
  • the final amount of oligonucleotide administered was 40 nmols per animal.
  • the treatments were applied by infusion into the left brain cortex of the rat, through an alzet pump implanted in the co-ordinates (AP -1.6, L +5.5, P -1.0) corresponding to the core of the infarcted area.
  • the alzet pump was filled with the oligonucleotide at 0.83 ⁇ M; the pump had a flow of 0.5 ⁇ L/hour, so the animals received 10 nmols of oligonucleotide every 24 hours period.
  • the animals in the control group received 12 ⁇ L of saline solution a day.
  • the capacity of the alzet pumps was for a 7 days infusion period, so the pumps were implanted 5 days before MCAO and were working since two days after injury.
  • the final amount of oligonucleotide administered was 70 nmols per animal .
  • the brains were removed and stained 48 hours after MCAO and the inf rct volume was quantified by image analysis.
  • Example 3 Expression of the Pentraxin I gene in a stroke model and an in vitro apoptotic model
  • the stroke model was validated for later DD studies by hybridization of samples from both hemispheres -ipsilateral and contralateral- after MCAO with ⁇ -actin as a control, and the heat shock protein 70 (HSP70) , described as an immediate- early gene induced after MCAO ( Figure 5) .
  • HSP70 heat shock protein 70
  • a selected band from DD experiments showed high homology to the previously described human and rat neuronal Pentraxin I .
  • the band from the stroke model was homologous to the rat Pentraxin I from base 1479 to 1877 (stop at base 1853), and the one from the apoptotic model from base 5127 to 5339.
  • this band was selected because there was a decreasing signal during the time course, but in the in vi tro apoptotic model there was an increase of intensity.
  • the stroke model was validated for later DD studies by hybridization of samples from both hemispheres -ipsilateral and contralateral- after MCAO with ⁇ -actin as a control, and the heat shock protein 70 (HSP70) , described as an immediate- early gene induced after MCAO ( Figure 5) .
  • HSP70 heat shock protein 70
  • samples from sham, 2 and 6 hours after MCAO were selected for the DD experiments .
  • a selected band from the DD experiments showed high homology to the previously described rat neuronal Pentraxin receptor.
  • oligonucleotide (sense and antisense) corresponding to bases 561 to 581 of the Pentraxin I gene was used to see the effect on the cell survival in the apoptotic model . As it is shown in Figure 13/1, only antisense treatment induces a significant reduction of the percentage of cell death. This is indicative that repression of the expression of the Pentraxin I protein has a neuroprotective effect.
  • An oligonucleotide (sense and antisense) corresponding to the bases 630 to 650 of the Pentraxin I gene was used to see the neuroprotective effect on the rat Stroke Model.
  • Polyclonal antibodies were obtained using a synthetic peptide homologous to rat Pentraxin I sequence.
  • a specific peptide, peptide 1 (Figure 4/1, panel B) , was conjugated to KLH for the immunization and to BSA for the screening ( Figure 14/1) .
  • the presence of specific antibodies was detected using for the coating the peptide 1 conjugate to BSA by means of two different linkers, SMP and SPDP.
  • a specific band around 100 kDa was detected after western blotting with extracts of two neuronal rat cell lines ( Figure 15/1) .
  • Polyclonal antibodies were obtained using a synthetic peptide homologous to rat Pentraxin receptor sequence.
  • a specific peptide, peptide 1 (Figure 4/II, panel B) , was conjugated to KLH for the immunization and to BSA for the screening ( Figure 14/11) .
  • the presence of specific antibodies was detected using for the coating the peptide 1 conjugate to BSA by means of two different linkers, SMP and SPDP.
  • a specific band around 45 kDa was detected after western blotting with extracts of all neuronal rat cell lines ( Figure 15/11) .
  • Example 13 Protein levels of Pentraxin I in the strock and in vitro apoptotic model.
  • rat Pentraxin I The expression of rat Pentraxin I was detected using a commercial monoclonal antibody and the standard western blot techniques .
  • the rat brain was dissected in: right hemisphere, non-infarcted left hemisphere, infarcted left hemisphere and cerebellum.
  • the extracts (on buffer: Tris-HCl 50 mM pH 7.4, 0.1% Triton X- 100, 5 mM EDTA, 250 mM NaCl and 10 ⁇ l/ml PMSF) were run using 20 ⁇ g per lane.
  • the specific 47 kDa specific band for Pentraxin I was detected (Transduction Laboratories, N35130) and compared to the signal of a housekeeping gene such as tubulin (ICN, 650952) ( Figure 17, panel I) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des séquences d'acides nucléiques codant pour le récepteur humain de la pentraxine et pour des protéines connexes, ainsi qu'une composition pharmaceutique comprenant une quantité thérapeutiquement efficace de (a) pentraxine I ou du récepteur humain de pentraxine, (b) un variant non fonctionnel de la protéine de (a), (c) un anticorps de la protéine de (a) ou de (b), (d) une séquence d'acides nucléiques codant pour la protéine de (a) ou de (b), (e) une séquence d'ARN antisens caractérisée en ce qu'elle est complémentaire à une pentraxine I ou à un ARNm de récepteur humain de pentraxine et en ce qu'elle peut se lier sélectivement audit ARNm, ladite séquence étant capable d'inhiber la synthèse de pentraxine I ou du récepteur humain de pentraxine, ou (f) un ribozyme caractérisé en ce qu'il est complémentaire à une pentraxine ou à un ARNm de récepteur humain de pentraxine et en ce qu'il peut sélectivement se lier au dit ARNm et le scinder, ce qui mène à l'inhibition de la synthèse de pentraxine I ou du récepteur humain de pentraxine. L'invention concerne, en outre, l'utilisation des composés ci-dessus pour le traitement de troubles neuronaux ou pour assurer un effet neuroprotecteur. Ces composés sont aussi utiles pour détecter une maladie associée à un trouble neuronal basé sur une expression sans régulation de ces protéines ou sur la présence de pentraxine I/récepteur humain de pentraxine n'ayant aucune activité biologique ou une activité biologique éventuellement réduite.
EP00979564A 1999-11-15 2000-11-15 Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes Withdrawn EP1230356A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00979564A EP1230356A2 (fr) 1999-11-15 2000-11-15 Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99122666 1999-11-15
EP99122666A EP1101820A1 (fr) 1999-11-15 1999-11-15 Pentraxin I et recepteur de la pentraxin, inhibiteurs de ces proteines et compositions pharmaceutiques comprenant ces composés
PCT/EP2000/011302 WO2001036626A2 (fr) 1999-11-15 2000-11-15 Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes
EP00979564A EP1230356A2 (fr) 1999-11-15 2000-11-15 Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes

Publications (1)

Publication Number Publication Date
EP1230356A2 true EP1230356A2 (fr) 2002-08-14

Family

ID=8239390

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99122666A Withdrawn EP1101820A1 (fr) 1999-11-15 1999-11-15 Pentraxin I et recepteur de la pentraxin, inhibiteurs de ces proteines et compositions pharmaceutiques comprenant ces composés
EP00979564A Withdrawn EP1230356A2 (fr) 1999-11-15 2000-11-15 Pentraxine i et recepteur de pentraxine, inhibiteurs de ces proteines et compositions pharmaceutiques contenant ces composes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP99122666A Withdrawn EP1101820A1 (fr) 1999-11-15 1999-11-15 Pentraxin I et recepteur de la pentraxin, inhibiteurs de ces proteines et compositions pharmaceutiques comprenant ces composés

Country Status (5)

Country Link
EP (2) EP1101820A1 (fr)
JP (1) JP2003514528A (fr)
AU (1) AU1700801A (fr)
CA (1) CA2389662A1 (fr)
WO (1) WO2001036626A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062785A2 (fr) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
JP2005518443A (ja) 2002-02-21 2005-06-23 クォーク バイオテック インコーポレーティッド 脳虚血または脳損傷を予防または治療する方法
ES2325779B1 (es) * 2007-12-05 2010-07-06 Consejo Superior De Investigaciones Cientificas Elementos reguladores de la actividad de np1 utiles para la elaboracion de medicamentos para el tratamiento o prevencion de enfermedades humanas neurodegenerativas, medicamentos asi obtenidos y sus aplicaciones.
ES2352630B1 (es) * 2009-07-14 2012-01-02 Consejo Superior De Investigaciones Científicas (Csic) Rna de interferencia utiles para la elaboracion de medicamentos para el tratamiento o prevencion de enfermedades humanas neurodegenerativas, medicamentos asi obtenidos y sus aplicaciones
ES2352925B1 (es) * 2009-07-14 2012-01-02 Consejo Superior De Investigaciones Cientificas (Csic) Rna de interferencia útiles para la elaboración de medicamentos para el tratamiento o prevención de enfermedades humanas neurodegenerativas, medicamentos así obtenidos y sus aplicaciones.
US10222386B2 (en) 2014-09-19 2019-03-05 The Johns Hopkins University Biomarkers of congnitive dysfunction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0136626A2 *

Also Published As

Publication number Publication date
EP1101820A1 (fr) 2001-05-23
WO2001036626A2 (fr) 2001-05-25
AU1700801A (en) 2001-05-30
WO2001036626A3 (fr) 2001-10-18
WO2001036626A9 (fr) 2002-09-12
JP2003514528A (ja) 2003-04-22
CA2389662A1 (fr) 2001-05-25

Similar Documents

Publication Publication Date Title
KR100728405B1 (ko) Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
EP0750628B1 (fr) Facteur-10 de croissance du fibroblaste
JPH11507332A (ja) 結合組織成長因子
EP1007074B1 (fr) Polypeptides specifiques de l'hypothalamus
KR20080028888A (ko) 신규 생리 물질 ｎｅｓｆａｔｉｎ과 그 관련 물질, 및그들의 용도
AU735794B2 (en) Don-1 gene and polypeptides and uses therefor
JPH10511936A (ja) ヒトソマトスタチン様受容体
EP1101820A1 (fr) Pentraxin I et recepteur de la pentraxin, inhibiteurs de ces proteines et compositions pharmaceutiques comprenant ces composés
JPH03169896A (ja) 脳因子
PT90019B (pt) Processo para a preparacao e purificacao de factor de choque termico humano
US6429010B1 (en) DNA encoding the human synapsin III gene and uses thereof
US20030054446A1 (en) Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
US7749758B2 (en) Human and mammalian stem cell-derived neuron survival factors
US20030026793A1 (en) Hypoxia inducing factors and uses thereof for inducing angiogenesis and improving muscular functions
CN101892237B (zh) 线粒体膜电位下降相关的多核苷酸及其编码多肽和用途
JPH08506654A (ja) 前立腺疾病の検出方法および治療方法
WO1999047671A2 (fr) Sequences d'adn codant pour la semaphorine-h et diagnostic du cancer metastatique
AU4500696A (en) Novel receptor tyrosine kinases
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
JP2001511005A (ja) ヒト再生関連セルピン−１（ｒａｓｐ−１）および使用方法
WO2001019864A1 (fr) Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation
US20040185442A1 (en) Novel polypeptide-human retinoic acid-responsive protein 53.57 and a polynucleotide encoding the same
WO2001012126A2 (fr) Regeneration de cardiomyocytes
CN1952133A (zh) 激活cre活性的多核苷酸及其编码多肽和用途
WO2000041537A2 (fr) Utilisation de la proteine desert hedgehog

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020430

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030930

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080502